Drug interactions
Glecaprevir / pibrentasvir + Metformin-repaglinide
Severity: Moderate
Glecaprevir / pibrentasvir and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Glecaprevir and pibrentasvir inhibit OATP1B1/1B3, which can raise plasma concentrations of repaglinide, an OATP1B1 substrate. Higher repaglinide exposure increases the risk of hypoglycemia. Antiviral therapy may also improve glycemia in patients with hepatitis C, adding to this risk.
What this interaction means in plain words
Glecaprevir / pibrentasvir and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Inhibition of hepatic OATP1B1/1B3 uptake transporters reduces repaglinide hepatic uptake and clearance.
What to do
Monitor blood glucose closely during hepatitis C treatment and reduce the repaglinide dose if hypoglycemia occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glecaprevir / pibrentasvir and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Frequently asked questions
Can I take Glecaprevir / pibrentasvir with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Glecaprevir / pibrentasvir and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Glecaprevir and pibrentasvir inhibit OATP1B1/1B3, which can raise plasma concentrations of repaglinide, an OATP1B1 substrate. Higher repaglinide exposure increases the risk of hypoglycemia. Antiviral therapy may also improve glycemia in patients with hepatitis C, adding to this risk.
How serious is the interaction between Glecaprevir / pibrentasvir and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose closely during hepatitis C treatment and reduce the repaglinide dose if hypoglycemia occurs.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
